Moffitt logo
    Search

    Choose a type to search within:

    All Doctors Clinical Trials Researchers
    search icon
    • Schedule
      New Patients
       
      Referring Physicians
    • Locations
      Magnolia
       
      McKinley
       
      Wesley Chapel
       
      International Plaza
       
      Moffitt at Memorial
       
      Fowler
       
      Telecomm/Intellicenter
    • Find a Doctor
    • MyMoffitt Portal
      Log In
       
      Enroll
    • Donate
    • 1-888-663-3488
    • image Search
    • Cancer Types & Treatments
        Cancers We Treat
      • Adrenal
      • Anal
      • Appendiceal (Appendix)
      • Astrocytoma
      • Basal Cell Carcinoma
      • Bladder
      • Bone Metastasis
      • Brain
      • Brain Tumor
      • Breast
      • Cervical
      • Cholangiocarcinoma (Bile Duct )
      • Colon
      • Colorectal
      • Cutaneous T-Cell Lymphoma
      • Ductal Carcinoma In Situ
      • Endometrial (Uterine)
      • Esophageal
      • Gallbladder
      • Gastrointestinal Carcinoid Tumor
      • GIST (Gastrointestinal Stromal Tumor)
      • Glioblastoma
      • Head and Neck
      • HER2 Positive Breast
      • Hodgkin Lymphoma
      • Inflammatory Breast
      • Invasive Ductal Carcinoma
      • Kidney (Renal Cell)
      • Leukemia
      • Liver (Hepatocellular)
      • Lung
      • Lymphomas (Hodgkin and Non-Hodgkin)
      • Melanoma
      • Meningioma
      • Merkel Cell Carcinoma
      • Mesothelioma
      • Metastatic Breast
      • Multiple Myeloma-Plasma Cell Tumor
      • Myelodysplastic Syndromes (MDS)
      • Neuroendocrine Tumor
      • Neurofibromatosis
      • Non-Hodgkin Lymphoma
      • Oral Cavity (Mouth)
      • Oral Cavity or Throat
      • Osteosarcoma
      • Ovarian
      • Pancoast Tumor
      • Pancreatic
      • Penile
      • Pituitary Adenoma
      • Prostate
      • Rectal
      • Sarcoma
      • Skin (Nonmelanoma)
      • Skull Base Tumors
      • Small Intestine
      • Spinal Tumor
      • Squamous Cell Carcinoma
      • Stomach (Gastric)
      • Testicular
      • Throat
      • Thymoma
      • Thyroid
      • Tongue
      • Tracheal
      • Triple Negative Breast
      • Vaginal
      • Vulvar
        Cancer Diagnostics and Treatments
      • Blood & Bone Marrow Transplant
      • Cardio-Oncology
      • Chemotherapy
      • Clinical Pathways
      • Clinical Trials
      • Endoscopic Procedures
      • Fertility Preservation
      • Gynecologic Oncology
      • Immunotherapy
      • Interventional Pain Management
      • Interventional Radiology
      • Personalized Medicine
      • Pharmacy
      • Radiation Therapy
      • Rehabilitation Services
      • Supportive Care Medicine
      • Surgical Care
      • Systemic Therapy
      • Targeted Therapy
      • Tumor Board
        Diagnostic Services
      • Radiology – Diagnostic Imaging and Interventional Radiology
      • Genetic Counseling and Genetic Testing
      • Pathology
      • Labwork and Bloodwork
      • Cancer Screenings
    • Patients & Families
        Patients and Families Resources Overview
      • International Referral Services
      • Moffitt Virtual Visits
      • Taking Care of Your Health
        Preparing For Your Appointment
      • Scheduling Your Appointment
      • MyMoffitt Patient Portal
      • Patient and Family Orientation
      • Patient Rights and Responsibilities
      • Medical Records
      • Traveling for Cancer Treatment
        Insurance & Financial Information
      • Insurance Coverage
      • Health Exchange
      • Medicare Coverage
      • Copay Assistance Program
      • Financial Assistance
      • Financial Information
      • Obtain a Cost Estimate
      • Understanding Your Bill
      • Frequently Asked Questions
        Programs & Support Services
        Patient and Family-Centered Care
        Cancer Survivorship
        Caregivers and Families
    • For Healthcare Professionals
        For Healthcare Professionals Overview
      • Clinical Perspectives
        Programs & Services
      • Adolescent & Young Adult (AYA)
      • Anesthesiology
      • BMT and Cellular Immunotherapy
      • Breast Oncology
      • Cardio-Oncology
      • Cutaneous Oncology
      • Diagnostic Imaging and Interventional Radiology
      • Endocrine Oncology
      • Gastrointestinal Oncology
      • Genetic Counseling
      • Genitourinary Oncology
      • Gynecologic Oncology
      • Head and Neck Oncology
      • Immunotherapy
      • Malignant Hematology
      • Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System
      • Neuro-Oncology
      • Pathology
      • Pharmacy
      • Radiation Oncology
      • Sarcoma
      • Screening & Prevention
      • Senior Adult Oncology
      • Supportive Care Medicine
      • Thoracic Oncology
        Physician Relations
        Continuing Education
      • Provider Conferences
      • Moffitt Grand Rounds
      • Multidisciplinary Programs
    • Research
        Research Overview
        CCSG Programs
      • Cancer Biology and Evolution
      • Cancer Epidemiology
      • Health Outcomes & Behavior
      • Immuno-Oncology
      • Molecular Medicine
        Divisions and Departments
      • Biostatistics and Bioinformatics
      • Cancer Epidemiology
      • Drug Discovery
      • Health Outcomes and Behavior
      • Immunology
      • Integrated Mathematical Oncology
      • Machine Learning
      • Metabolism and Physiology
      • Molecular Oncology
      • Tumor Biology
        Centers and Institutes
      • Institutes
      • Centers of Excellence
        Shared Resources
      • Analytic Microscopy
      • Biostatistics and Bioinformatics
      • Cancer Pharmacokinetics and Pharmacodynamics
      • Cell Therapies
      • Chemical Biology
      • Collaborative Data Services
      • Flow Cytometry
      • Gene Targeting
      • Molecular Genomics
      • Participant Research, Interventions, and Measurement Core (PRISM)
      • Proteomics and Metabolomics
      • Quantitative Imaging Core
      • Small Animal Imaging Lab
      • Tissue
        Research Education and Training
      • Office of Postdoctoral Affairs
      • Office of Graduate Affairs
      • Office of Undergraduate and Visiting Scholar Affairs
      • What We Provide
        Community Outreach, Engagement, and Equity
      • About Us
      • Catchment Area Cancer Data
      • Moffitt Outreach in the Community
      • Research in the Community
      • Education and Outreach Resources
      • Get Involved
        Innovation and Industry Alliances
      • Available Technologies
      • Business of Biotech
      • Events
      • Internship Programs
      • Technology And Innovation Fund
      • Contact Us
    • Training & Education
        Training and Education Overview
      • Moffitt Innovators of Tomorrow Symposium
        Medical Education
      • Program Staff/Contact Us
      • Our Training Programs
      • Salary and Benefits
        Research Education and Training
      • Office of Postdoctoral Affairs
      • Office of Graduate Affairs
      • Office of Undergraduate and Visiting Scholar Affairs
      • What We Provide
      • Where Are They Now
        Nursing Education
      • Oncology Nurse Residency Program
      • Ambulatory Care Oncology Nurse Residency Program
      • Registered Nurse
      • Nurse Anesthetist
      • Nurse Practitioner
        Health Professional Education
        Continuing Education
        Other Educational Programs
    • Give
        Give Overview
        Ways to Give
      • Cash, Stock or Other Assets
      • Planned Giving
      • Philanthropic Foundation Giving
      • Corporate Partnership
      • Employer Matching Gifts
      • Endowment Gifts
      • Other Ways to Donate
        Get Involved
      • Become a Member
      • Join a Community Partner Event
      • Volunteer Your Time
      • Miles for Moffitt
      • Magnolia
      • Mission Possible Sarasota Luncheon
      • Discovery Series Webinars
        Why Give?
      • About the Moffitt Foundation
      • FAQ
      • Financials and Stewardship
      • Contact the Foundation
      • You Can Make a Difference
      • 2021 Annual Foundation Impact Report
    1. Home
    2. Newsroom
    3. Press Release Archive
    4. 2009
    5. October Marks Breast Cancer Awareness Month
    • click to share
      Facebook
      Twitter
      Linkedin
      Pinterest
      Email
    • click to print

    October Marks Breast Cancer Awareness Month

    October 06, 2009

    Moffitt Cancer Center Experts Available For Comment

    WHAT:  Moffitt physicians are available during October to discuss the latest on breast cancer prevention, screening, treatment and research.

    WHO:              Dr. Christine Laronga, M.D., F.A.C.S., program leader of the Don and Erika Wallace Comprehensive Breast Program

                            Dr. Hyo (Heather) S. Han, M.D., assistant member of the breast program

                            Dr. Roohi Ismail-Khan, M.D., assistant member of the breast program

                            Dr. Nazanin Khakpour, M.D., F.A.C.S., assistant member of the breast program

                            Dr. John V. Kiluk, M.D., assistant member of the breast program who specializes in male breast cancer

                            Dr. M. Catherine Lee, M.D., assistant member of the breast program

                            Dr. Loretta Loftus, M.D., senior member of the breast program

                            Dr. Susan E. Minton, D.O., associate member of the breast program

                            Dr. Tuya Pal, M.D., associate member of the breast program

                            Dr. Hatem Soliman, M.D., assistant member of the breast program

                            Dr. Rebecca Sutphen, M.D., director of the Genetic Counseling & Testing Service

     

    CONTACT:Patty Kim, media relations coordinator, can be reached at (813) 745-7322 or patty.kim@moffitt.org.

    STATISTICS: In 2009, an estimated 192,370 women and 1,910 men will be diagnosed with breast cancer. One in eight women will be diagnosed with breast cancer during their lifetime.

                            Risk factors for developing breast cancer include older age, menstruating at an early age, older age at first birth or never having given birth, family history of breast cancer, breast tissue that is dense on a mammogram, hormone therapy, drinking alcoholic beverages and being Caucasian. To help prevent breast cancer, women should exercise regularly to maintain a healthy weight and limit their alcohol consumption.

    STUDIES:|Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer (MCC 14937)   Principle Investigator: Loretta Loftus, MD

    • The purpose of this study is to find out if adding an investigational drug (bisphosphonate) to hormonal therapy or chemotherapy will help prevent cancer from spreading to the bones or other parts of the body. Bisphosphonates are a group of drugs that have strong effects on bones and have been shown to strengthen them in many patients who take them. Clodronate and ibandronate are not approved by the Food and Drug Administration (FDA) for this disease. 

    Women with primary invasive breast adenocarcinoma (stages I, II or III) with no evidence of metastatic disease are encouraged to contact Angela Stephens, BS, CCRP, 813-745-1807, for more information about eligibility criteria.

    |Liposuction for Arm Lymphedema Following Breast Cancer Surgery (MCC 14728) Principle Investigator: Christine Laronga, MD, PhD

    • The purpose of this study is to determine if a less invasive procedure such as liposuction can be used to effectively reduce arm lymphedema (swelling of the arm) resulting from breast cancer treatment. The standard surgery involves the removal of large portions of skin and tissue leaving a large scar. This less invasive procedure (liposuction) uses 3 to 4 tiny puncture sites and a vacuum tube, leaving minimal scars. 

    Women who have undergone breast cancer surgery and who have lymphedema (stage 2 or 3) with no signs of active infection are candidates for the procedure. Patients must be free of active disease recurrence at study entry. For more information, contact Dr. Mira (Mensura) Lacevic, CRC, 813-745-8304 for more information about eligibility criteria.

    |Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA, vorinostat) in Combination with Tamoxifen for Patients with Advanced Breast Cancer Who Have Failed Prior Anti-Hormonal Therapy (MCC 14662)      Principle Investigator: Susan Minton, DO

    • The purpose of this study is to find out if patients with breast cancer that has spread,
    1. will benefit from adding the new drug vorinostat to the old drug tamoxifen.
    2. what effects (good and bad) vorinostat combined with tamoxifen may have on breast cancer.
    3. what changes this combination of drugs may cause in blood and tumor cells.

    Patients with measurable locally advanced or metastatic breast cancer, which is estrogen- or progresterone- receptor positive, are encouraged to call Dr. Mira (Mensura) Lacevic, CRC, 813-745-8304 for more information about eligibility criteria.

    |Phase II, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment with a Non-Steroidal Aromatase Inhibitor (MCC 15435)   Principle Investigator: Roohi Ismail-Khan, MD

    • The purpose of this study is:
    1. to evaluate the safety of the experimental drug SNDX-275 when it is given with the approved drug exemestane (Aromasin®) and
    2. to see if it will lengthen the amount of time until further progression of disease.  

    Postmenopausal women with estrogen-receptor positive breast cancer who have recurred or progressed on prior treatment with an aromatase inhibitor are encouraged to contact Dr. Mira (Mensura) Lacevic, CRC, 813-745-8304 for more information about eligibility criteria.

    |3-D Ultrasound for Assessment of Treatment Effect in Neo-adjuvant Breast Cancer Patients: a Phase II Trial  (MCC 15617)   Principle Investigator: Marie Catherine Lee, MD

    • The purpose of this study is to see if a picture of the patient’s breast taken with a 3D ultrasound will provide a better image than a regular ultrasound or an MRI (Magnetic resonance imaging). 

    Patients with histologically confirmed invasive breast cancer and consent to undergo a standard neo-adjuvant chemotherapy regimen that will be administered at Moffitt Cancer Center are encouraged to contact Dr. Mira (Mensura) Lacevic, CRC, 813-745-8304 for more information about eligibility criteria.

    |Phase II Evaluation of a Once Every 28 Days Dosing Regimen for LY573636-Sodium in Patients with Metastatic Breast Cancer (MCC 15998) Principle Investigator: Hatem Soliman, MD

    The purpose of this study is to estimate the response rate for LY573636 in patients with metastatic breast cancer who have received two or more prior treatment regimens. For more information, contact Dr. Mira (Mensura) Lacevic, CRC, 813-745-8304 for more information about eligibility criteria.

    |A Study to Establish Proof-of-Biology for MK-0646 in Breast Cancer (MCC 15667)   Principle Investigator: Roohi Ismail-Khan, MD

    • The purpose of this study is to:
    1. Find out if a new drug called MK-0646 can change the biology of the patient's tumor.
    2. Find out if the change in the biology of the patient's tumor from MK-0646 is related to whether the tumor has a protein called IGF1R.
    3. Find out if MK-0646 causes formation of a type of antibody (a protein that attacks foreign particles in the body).
    4. Measure how much drug is in the patient's body and how it relates to the change in the biology of the tumor.  

    Women with operable stage I to IIIa invasive breast cancer that is ER, PR, and HER2 negative are encouraged to seek more information by contacting Leticia Tetteh, BSN, 813-745-4617.

    |Phase I Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CNF2024 as a Single-Agent Treatment in Subjects with HER2- Advanced Breast Cancer or in Combination with Trastuzumab in Subjects with HER2+ Advanced Breast Cancer  (MCC 15002)       Principle Investigator: Roohi Ismail-Khan, MD

    • The purpose of this study is to find the highest dose of the drug CNF2024 that can be given safely, measure levels of CNF2024 in the blood, and determine if CNF2024 can stop breast cancer cells from growing.

    Patients who have had disease progression on at least one standard hormonal or chemotherapeutic regimen for advanced metastatic adenocarcinoma of the breast are encouraged to call Luz Diez, BSN, 813-745-4625, for further information about eligibility for this study.

    |A Phase I Investigation of the Combination of MK-2206, Trastuzumab and Lapatinib in HER2+ Solid Tumors (MCC 15999)     Principle Investigator: Hyo Han, MD

    • The purpose of this study is to test the safety of the research study drug, MK-2206 in combination with the drugs trastuzumab (Herceptin®) and lapatinib (Tykerb®).

    Patients with locally advanced or metastatic HER2+ solid tumors, which may include, but are not limited to, breast cancer, gastric cancer, ovarian cancer, NSCLC and others, are encouraged to contact Kathy Sergi, RN, 813-745-4616, for more information about eligibility.

    |A Phase I Dose Escalation Study of MK-2206 in Combination with Standard Doses of Selected Chemotherapies or Targeted Agents in Patients with Locally Advanced or Metastatic Solid Tumors (MCC 15776) Principle Investigator: Susan Minton, DO

    • The purpose of this study is to test the safety and tolerability of the research drug, MK-2206, in combination with other chemotherapy drugs and targeted agent drugs.

    Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors who lack curative options or who have failed to respond to standard therapy may call Luz Diez, BSN, 813-745-4625, for further information about eligibility for this study.

    |A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients with Advanced Malignant Solid Tumors (MCC 15844)   Principle Investigator: Hyo Han, MD

    • The purpose of this study is to look at the safety and tolerability of the drug Genz-644282, its effects, if any, on advanced malignant solid tumors, as well as how the body uses, stores, and gets rid of Genz-644282. 

    Patients with advanced malignant solid tumors for whom no standard therapeutic option exists may contact Kathy Sergi, RN, 813-745-4616, for more information about this study.

    |Phase I Dose Escalation Study of LY2090314 in Patients with Advanced or Metastatic Cancer in Combination with Pemetrexed and Carboplatin (MCC 15278) Principle Investigator: Jhanelle Gray, MD

    • The purpose of this study is to study the effects of the drug LY2090314, which is a new drug that is not yet approved by the Food and Drug Administration (FDA), in patients with advanced cancer.

    Patients who have cancer that is advanced or metastatic, for which no proven effective therapy is known, with measurable or unmeasurable disease, are encouraged to contact Leticia Tetteh, BSN, 813-745-4617, for more information about this study.

    RESOURCES:   Lifetime Cancer Screening & Prevention Center

                            General Information About Breast Cancer

                            Breast Cancer Prevention

    Breast Cancer Treatment Options

                            Breast Cancer And Pregnancy

    Male Breast Cancer

    FACTors Program

                            Moffitt Support Groups

                            Cancer Answers

                            Facing Our Risk of Cancer Empowered

    Moffitt Events Calendar

    Twitter

    Tweets by MoffittNews
    footer logo
    • BROWSE
      • Cancer Types & Treatments
      • Careers
      • Clinical Trials
      • Diagnostic Services
      • Education & Training
      • Locations
      • Patients & Families
      • Research
    • ABOUT
      • About Moffitt
      • Available Technologies
      • Calendar of Events
      • Clinical Perspectives
      • Community Benefit
      • Diversity
      • Endeavor
      • Newsroom
      • Our Outcomes
      • Partnerships
      • Taking Care of Your Health
    • ACTION
      • Appointments
      • Find a Doctor
      • Patient Portal
      • Refer a Patient
      • Referring Provider Portal
      • Staff Login
      • Staff Access
      • Volunteer
      • Ways to Give
    Call Today 1-888-663-3488
    Link to FaceBook
    Facebook
    Link to Twitter
    Twitter
    Link to Instagram
    Instagram
    Link to YouTube
    YouTube
    nci designated comprehensive cancer center award
    nccn award
    magnet recognized award
    diversity inc award
    • Site Map
    • Privacy Policy
    • Terms & Conditions
    • Unsubscribe
    • State Nonprofit Disclosures
    • Donor Privacy
    • Notice of Privacy Practices
    • Visitor Policy
    ©Copyright 2023 Moffitt Cancer Center
    ✕

    Request an Appointment at Moffitt Cancer Center

    Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.

    NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.

    REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.

    Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.


    Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub

    ✕

    Access Your Portal

    For Patients

    A secure website for patients to access their medical care at Moffitt.

    PATIENT PORTAL LOGIN

    For Physicians

    An online resource for referring physicians and their staff.

    PROVIDER PORTAL LOGIN

    For Moffitt Staff

    For Moffitt faculty & staff members to access MoffittNet applications.

    STAFF PORTAL LOGIN

    ✕

    Call: 1-888-663-3488

    Call: 1-888-663-3488

    Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.

    Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday